Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
IXJ vs VHT: Weighing Global and U.S. Healthcare ETFs

IXJ vs VHT: Weighing Global and U.S. Healthcare ETFs

Key Takeaways

  • IXJ is a global healthcare ETF spanning U.S. and international pharmaceutical, biotech, and medical-device names, while VHT tracks a U.S.-only healthcare index.
  • Both funds have advanced strongly in recent months, but VHT holds a modest edge in year-to-date (YTD) return, aided by heavyweight exposure to large U.S. pharmaceutical leaders.
  • IXJ has shown notable relative momentum improvement, climbing toward the top of its healthcare-fund peer group in recent weeks.
  • Tickeron AI Verdict: IXJ — the AI currently favors its improving trend consistency and broader global diversification.
  • For more detail on each fund's developments and daily moves, explore IXJ Major News, IXJ Today's Price Move, VHT Major News, and VHT Today's Price Move.
  • To see how AI trading systems are positioning across the market, explore the curated Trending AI Robots page.

Why These Two Funds Matter

Healthcare ETFs provide diversified exposure to a defensive sector driven by innovation, and IXJ and VHT rank among the most followed choices. Both track healthcare equity indexes passively, yet they differ in geographic reach, fees, and concentration levels. This matters for investors considering a global healthcare allocation versus a U.S.-only approach, especially when assessing relative performance and current market positioning. From what I see, understanding the distinctions in holdings, momentum, and risk can clarify which option aligns better with a given strategy.

IXJ Overview and Recent Performance

IXJ, the iShares Global Healthcare ETF, tracks the S&P Global 1200 Health Care Sector Index and holds exposure to more than 100 healthcare companies around the world. The portfolio leans heavily toward pharmaceuticals, biotech, and life sciences, with a smaller allocation to healthcare equipment and services. Even with its global mandate, U.S. large-cap names exert the strongest influence. In recent weeks, IXJ has traded in the upper part of its 52-week range and delivered a solid YTD gain in the mid-to-high teens. Its momentum ranking within the healthcare sector category improved markedly over the past quarter, indicating stronger relative strength. The fund carries an expense ratio near 0.4% and a relatively low three-year beta, consistent with the defensive nature of its holdings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

VHT Overview and Recent Performance

VHT, the Vanguard Health Care ETF, follows the MSCI US Investable Market Health Care 25/50 Index and focuses exclusively on U.S.-listed healthcare companies across large-, mid-, and small-cap segments. Top holdings include major U.S. pharmaceutical, biotech, and health-insurance names such as Eli Lilly, Johnson & Johnson, AbbVie, Merck, and UnitedHealth Group. Over recent weeks, VHT has also traded near the upper end of its 52-week range amid broad strength in U.S. healthcare equities. Its YTD return has edged slightly ahead of IXJ, supported by concentration in high-momentum U.S. pharmaceutical leaders. The fund benefits from a low expense ratio around 0.10% and significantly larger assets under management, which supports strong liquidity and tight spreads. Its U.S.-only focus, however, means it misses international healthcare growth opportunities.

Head-to-Head Comparison

The key difference between the two funds lies in geographic scope. IXJ combines U.S. and international exposure, which can help diversify single-country regulatory and policy risks, whereas VHT concentrates entirely on the U.S. healthcare sector. On cost, VHT is notably cheaper, with an expense ratio roughly one-quarter that of IXJ, and its larger AUM supports higher liquidity. In terms of recent momentum, both have rallied, though the drivers vary. VHT has benefited from gains concentrated in a handful of large U.S. pharmaceutical and biotech leaders, delivering strong returns alongside higher single-name concentration. IXJ, by contrast, has shown sharper improvement in relative strength versus its healthcare-fund peers, pointing to a broadening and accelerating trend. Risk profiles remain broadly similar, though IXJ’s lower beta and diversified country mix may provide a somewhat smoother ride, while VHT’s focused U.S. allocation offers purer exposure to domestic healthcare strength.

Tickeron AI Verdict

Based on factors such as trend consistency, relative momentum, diversification, and positioning, Tickeron’s AI currently leans toward IXJ. The fund’s sharp improvement in relative strength within its healthcare category signals an accelerating, well-supported trend, while its global mandate widens the pool of potential growth drivers beyond a single market. VHT remains a compelling lower-cost option with strong U.S. exposure, but its heavier concentration and slightly less favorable momentum trajectory place it marginally behind in this comparison. This assessment is probabilistic rather than definitive and reflects current market conditions, which can shift.

Exploring AI-Driven Insights

In my research process, I frequently rely on Tickeron’s Trending AI Robots to gauge market positioning. These systems help identify trends across thousands of tickers, providing a data-backed view that complements traditional analysis. For those looking at funds like IXJ and VHT, checking the trending bots can add valuable perspective on how AI trading systems are aligning with current conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IXJ, VHT

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


IXJ sees MACD Histogram just turned negative

IXJ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 40 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IXJ moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 68 cases where IXJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

IXJ broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 66 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 218 of 263 cases where IXJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to track the S&P Global 1200 Health Care (Sector) Capped IndexTM. The fund seeks to track the investment results of the S&P Global 1200 Health Care (Sector) Capped IndexTM (the “underlying index”), which measures the performance of companies that S&P Dow Jones Indices LLC (the “index provider” or “SPDJI”), a subsidiary of S&P Global, Inc., deems to be a part of the healthcare sector of the economy and that SPDJI believes are important to global markets. The underlying index is a subset of the S&P Global 1200, which is designed to measure the performance of large-capitalization stocks from major global markets, as determined by SPDJI.

Market Cap

The average market capitalization across the iShares Global Healthcare ETF (IXJ) ETF is 109.21B. The market cap for tickers in the group ranges from 9.59B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is HSIC at 9.59B.

High and low price notable news

The average weekly price growth across all stocks in the iShares Global Healthcare ETF (IXJ) ETF was 4%. For the same ETF, the average monthly price growth was 34%, and the average quarterly price growth was 334%. REGN experienced the highest price growth at 5%, while MRNA experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the iShares Global Healthcare ETF (IXJ) ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was -13% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 44
Price Growth Rating: 30
SMR Rating: 57
Profit Risk Rating: 66
Seasonality Score: 30 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.